Latest news with #SinoBiopharmaceutical
South China Morning Post
23-05-2025
- Health
- South China Morning Post
US approves China-invented painkiller that could reduce fentanyl overdoses
The US Food and Drug Administration (FDA) has approved the first China-invented painkiller designed as a non-opioid alternative, giving it the potential to curb fentanyl-related overdose deaths. Qamzova, developed by Nanjing-based biotech firm Delova, is the world's first long-acting injectable analgesic – offering 24-hour pain relief through a single daily injection and marking a milestone for China's growing pharmaceutical industry. The non-steroidal anti-inflammatory (NSAID) medication belongs to the same group of painkillers as aspirin and ibuprofen. It contains a high concentration of meloxicam, a compound commonly used to reduce pain and inflammation. According to Sino Biopharmaceutical , the Chinese conglomerate that owns the commercial rights to Qamzova, clinical trials showed it was effective in reducing post-surgical reliance on opioids. By providing a safer, long-acting treatment for moderate-to-severe pain, Qamzova directly addresses the US overdose epidemic fuelled by addictive opioids, including fentanyl – a synthetic drug linked to tens of thousands of deaths annually. Qamzova's arrival underscores China's rising role in innovative medicines development while offering healthcare professionals a critical tool to mitigate opioid dependency risks and improve patient recovery.
Forbes
27-04-2025
- Business
- Forbes
U.S. FDA Approves China-Produced Cancer Drug
An Akeso logo is displayed on the screen of an iPad. (Photo Illustration by Sheldon Cooper/SOPA ... More Images/LightRocket via Getty Images) The U.S. Food and Drug Administration this week granted permission for the use of a new cancer drug from China despite high-profile strains in ties between the two countries. Akeso said on Thursday it has received approval for treatments with penpulimab-kcqx, which is used in the fight against nasopharyngeal cancer, or NPC. In a separate announcement, the drug co-developer Sino Biopharmaceutical also noted FDA approval of the marketing of penpulimab. NPC, a type of head and neck cancer, starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull, according to a description by the American Cancer Society. Cancer starts when cells begin to grow out of control, it noted. China, the world's most populous nation, had a reported 3.2 million new cancer cases last year. A large number of cases has made the country one of the world's most important markets for cancer drugs. Rare in most parts of the world, NPC is more common in certain parts of South Asia, the Middle East, and North Africa. In some parts of China there have been as many as 21 cases per 100,000 people, the American Cancer Society has said. A logo of Sino Biopharmaceutical Limited hangs on a building at the central business district in ... More Beijing. (Photo by VCG/VCG via Getty Images) Sino Biopharmaceutical, which listed on the Hong Kong Stock Exchange in 2000, is controlled by the billionaire family of Tse Ping. Akeso CEO Michelle Xia, who also goes by Xia Yu, ranked No. 20 on a list of China's top businesswomen published earlier this year by Forbes China, the licensed Chinese-language edition of Forbes. Apple Supplier's Chairman Leads New List Of China's Top Businesswomen CATL Battery Billionaire And Wife Donate $137 Million To Fudan
Yahoo
24-03-2025
- Business
- Yahoo
Asian Market Insights: Sino Biopharmaceutical And 2 Other Prominent Penny Stocks
Amidst a backdrop of global economic uncertainty and fluctuating market indices, Asian markets are capturing attention with their unique investment opportunities. Penny stocks, often associated with smaller or newer companies, continue to intrigue investors due to their potential for growth and affordability. While the term may seem outdated, these stocks remain relevant as they offer a mix of financial strength and promising prospects; this article will explore three such penny stocks that stand out in the Asian market landscape. Name Share Price Market Cap Financial Health Rating Interlink Telecom (SET:ITEL) THB1.46 THB2.03B ★★★★☆☆ Chumporn Palm Oil Industry (SET:CPI) THB2.80 THB1.77B ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.215 SGD42.83M ★★★★★★ Anchun International Holdings (SGX:BTX) SGD0.32 SGD14.99M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.36 SGD9.32B ★★★★★☆ Jiumaojiu International Holdings (SEHK:9922) HK$3.28 HK$4.58B ★★★★★★ Bosideng International Holdings (SEHK:3998) HK$4.13 HK$47.34B ★★★★★★ Lever Style (SEHK:1346) HK$1.29 HK$818.88M ★★★★★★ China Zheshang Bank (SEHK:2016) HK$2.56 HK$83.02B ★★★★★★ Xiamen Hexing Packaging Printing (SZSE:002228) CN¥3.09 CN¥3.58B ★★★★★★ Click here to see the full list of 1,151 stocks from our Asian Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Sino Biopharmaceutical Limited is a research and development pharmaceutical conglomerate operating in the People's Republic of China, with a market cap of approximately HK$66.19 billion. Operations: The company generates revenue primarily from its Modernised Chinese Medicines and Chemical Medicines segment, amounting to CN¥27.45 billion. Market Cap: HK$66.19B Sino Biopharmaceutical Limited, with a market cap of HK$66.19 billion, has shown robust earnings growth of 70.9% over the past year, surpassing the industry average. The company's net profit margins improved to 7.7%, and its debt is well covered by operating cash flow. Recent developments include promising clinical trial results for Rovadicitinib, a novel drug for chronic graft-versus-host disease, and strategic alliances to expand its drug pipeline in respiratory treatments with QP001 and CPX102 projects. However, the company faces challenges such as increased debt-to-equity ratio and recent removal from the Hang Seng China Enterprises Index. Get an in-depth perspective on Sino Biopharmaceutical's performance by reading our balance sheet health report here. Understand Sino Biopharmaceutical's earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: China Zheshang Bank Co., Ltd. offers a range of commercial banking products and services in Mainland China, with a market capitalization of HK$83.02 billion. Operations: The bank generates CN¥38.47 billion in revenue from its operations in Mainland China. Market Cap: HK$83.02B China Zheshang Bank, with a market cap of HK$83.02 billion, presents a mixed picture for penny stock investors. The bank's earnings have grown by 9.2% over the past year, outpacing industry averages and showing accelerated growth compared to its five-year average. It maintains an appropriate level of non-performing loans at 1.5%, and its funding is primarily low-risk through customer deposits, which are less risky than external borrowing. However, the management team is relatively inexperienced with an average tenure of 1.3 years, and while trading at good value below fair estimates, it has an unstable dividend track record. Click here to discover the nuances of China Zheshang Bank with our detailed analytical financial health report. Examine China Zheshang Bank's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Zhejiang Reclaim Construction Group Co., Ltd. operates in the construction industry and has a market cap of CN¥3.27 billion. Operations: The company's revenue for the segment in China is CN¥2.23 billion. Market Cap: CN¥3.27B Zhejiang Reclaim Construction Group, with a market cap of CN¥3.27 billion, offers a complex profile for penny stock investors. Despite being unprofitable, it has reduced losses by 38.1% annually over five years and maintains more cash than its total debt. The company's short-term assets match its liabilities at CN¥3.9 billion each, providing some balance sheet stability despite profitability challenges. Its debt to equity ratio has improved to 32.8% from 48.6% in five years, and the board is experienced with an average tenure of 3.1 years, though management's experience remains unclear due to insufficient data. Take a closer look at Zhejiang Reclaim Construction Group's potential here in our financial health report. Review our historical performance report to gain insights into Zhejiang Reclaim Construction Group's track record. Explore the 1,151 names from our Asian Penny Stocks screener here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1177 SEHK:2016 and SZSE:002586. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
19-02-2025
- Business
- Yahoo
Discovering Value: 3 Penny Stocks With At Least US$700M Market Cap
Global markets have shown resilience, with U.S. stock indexes climbing toward record highs despite inflationary pressures and economic uncertainties. In this context, identifying stocks that offer both value and growth potential is crucial for investors looking to navigate these conditions effectively. Penny stocks, though often considered niche investments, can present unique opportunities when supported by strong financials—highlighting smaller or newer companies that may provide stability alongside the potential for significant returns. Name Share Price Market Cap Financial Health Rating DXN Holdings Bhd (KLSE:DXN) MYR0.53 MYR2.64B ★★★★★★ Bosideng International Holdings (SEHK:3998) HK$3.87 HK$44.43B ★★★★★★ Warpaint London (AIM:W7L) £4.10 £331.23M ★★★★★★ Begbies Traynor Group (AIM:BEG) £0.938 £149.49M ★★★★★★ Datasonic Group Berhad (KLSE:DSONIC) MYR0.335 MYR932.02M ★★★★★★ Polar Capital Holdings (AIM:POLR) £4.98 £480.06M ★★★★★★ Hil Industries Berhad (KLSE:HIL) MYR0.84 MYR278.83M ★★★★★★ MGB Berhad (KLSE:MGB) MYR0.695 MYR411.2M ★★★★★★ Embark Early Education (ASX:EVO) A$0.79 A$144.95M ★★★★☆☆ Next 15 Group (AIM:NFG) £3.15 £313.29M ★★★★☆☆ Click here to see the full list of 5,690 stocks from our Penny Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Sino Biopharmaceutical Limited is a research and development-focused pharmaceutical conglomerate operating in the People's Republic of China, with a market cap of HK$60.92 billion. Operations: The company generates revenue primarily from its Modernised Chinese Medicines and Chemical Medicines segment, which accounts for CN¥27.45 billion. Market Cap: HK$60.92B Sino Biopharmaceutical Limited has recently gained approval for its Tulobuterol Patches, marking a significant milestone in the treatment of obstructive airway diseases. The company is actively pursuing marketing applications for several innovative drugs, including Benmelstobart Injection and Anlotinib Hydrochloride Capsules, targeting various cancers. Financially, Sino Biopharmaceutical demonstrates robust short-term asset coverage of liabilities and maintains more cash than total debt. While earnings have declined over five years, recent profit growth is notable at 70.9%, outpacing the industry average. Share repurchases aim to enhance shareholder value amidst stable weekly volatility and experienced management oversight. Navigate through the intricacies of Sino Biopharmaceutical with our comprehensive balance sheet health report here. Gain insights into Sino Biopharmaceutical's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★★★ Overview: China Zheshang Bank Co., Ltd. offers a range of commercial banking products and services in Mainland China, with a market cap of HK$80.95 billion. Operations: The bank generates revenue of CN¥38.47 billion from its operations in Mainland China. Market Cap: HK$80.95B China Zheshang Bank presents a mixed picture for penny stock investors. With a market cap of HK$80.95 billion and revenue of CN¥38.47 billion, it is not pre-revenue, indicating operational stability. The bank's net profit margins have improved to 37%, and its earnings growth of 9.2% surpasses the industry average, suggesting potential value despite low return on equity at 7.9%. The management team is relatively inexperienced with an average tenure of 1.2 years, which could pose challenges in strategic execution. However, the bank's funding primarily from customer deposits minimizes risk exposure amidst stable weekly volatility. Get an in-depth perspective on China Zheshang Bank's performance by reading our balance sheet health report here. Explore China Zheshang Bank's analyst forecasts in our growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Lepu Biopharma Co., Ltd. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of cancer-targeted therapies and immunotherapies both in China and internationally, with a market cap of HK$5.58 billion. Operations: The company generates revenue of CN¥205.08 million from the sales of pharmaceutical products and the research and development of new drugs. Market Cap: HK$5.58B Lepu Biopharma, with a market cap of HK$5.58 billion and revenue of CN¥205.08 million, remains unprofitable but has reduced losses by 27.6% annually over the past five years. The company recently entered an exclusive licensing agreement with ArriVent BioPharma for MRG007, securing upfront payments totaling US$47 million and potential milestones up to US$1.16 billion, enhancing its financial outlook. Despite short-term liabilities exceeding assets, Lepu maintains a satisfactory net debt to equity ratio of 15.9% and has sufficient cash runway for over a year based on current free cash flow projections amidst high share price volatility. Unlock comprehensive insights into our analysis of Lepu Biopharma stock in this financial health report. Understand Lepu Biopharma's earnings outlook by examining our growth report. Discover the full array of 5,690 Penny Stocks right here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1177 SEHK:2016 and SEHK:2157. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
